John Libbey Eurotext



Phage therapy in bone and joint infection: history, scientific basis, feasibility and perspectives in France Volume 24, issue 1, Janvier-Février 2020


  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
Frédéric Laurent on behalf of the Lyon BJI study group 1 2 3 4
1 Service de maladies infectieuses et tropicales,
hôpital de la Croix-Rousse, Hospices Civils de Lyon,
93 grande rue de la Croix-Rousse,
69004 Lyon, France
2 Université Claude Bernard Lyon 1,
43 Boulevard du 11 Novembre 1918,
69100 Villeurbanne
3 Centre de références des IOA complexes de Lyon,
CRIOAc Lyon, Hôpital de la Croix-Rousse,
93 Grande Rue de la Croix-Rousse,
69004 Lyon, France
4 Centre international de recherche en infectiologie (CIRI),
Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1,
7 rue Guillaume Paradin, 69007 Lyon
5 Laboratoire de Pharmacie galénique industrielle, UMR-CNRS 5305,
Plateforme Fripharm,
ISPB-Faculté de Pharmacie,
Université Claude-Bernard Lyon 1,
8, avenue Rockefeller,
F-69373 Lyon Cedex 08, France
* Correspondance

Background Bacteriophages are viruses that target bacteria. There are several families, such as Myoviridae, Siphoviridae or Podoviridae. They have high environmental prevalence, especially in aqueous media such as salt or fresh water, drains and soil. They seem to play a major role in bacteriological ecology in nature. Each is specific to one bacterial species. They may show a lysogenic cycle, integrating the bacterial genome using an integrase and thus promoting genetic exchange. Then they become [...]